Shares of Precision BioSciences DTIL rallied 23.8% on Tuesday after the company’s announcement that the FDA has granted Fast ...

The Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-HBV, an investigational gene editing therapy for adults with chronic hepatitis B.

Virology researchers have found that a specific protein modification to the immune protein MDA5 is key to how our bodies detect and respond to viruses and viral replication. The publication explains ...

The U.S. capacity to battle hepatitis B and C has been leveled a devastating blow with the recent closure of the CDC’s ...

Genetic approaches to prevent viral replication in essential, normal tissues is critical, and a secondary mechanism to inactivate the virus should ideally be available. Finally, the virus must be ...

Discover a recent study that explored how CT could also help assess fatty liver using 3D automated volumetric analysis.

Chronic HBV was associated with increased risk for adverse COVID-19 outcomes, but the risk was lower among coinfected patients vaccinated against COVID-19.

An in-depth look at Hepatitis D, why it’s so severe, and how new therapies bring hope for better treatment and prevention.

Kolkata: After a successful pilot project, Bengal govt is set to roll out a triple elimination programme for HIV, hepatitis B ...

Catching HBV early can make a world of difference. Medical professionals typically use blood tests that check for signs of the virus in the body, such as HBV antigens or antibodies. They also ...

Durham-based Precision BioSciences Inc. has received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for PBGENE-HBV, an in vivo gene editing program designed ...

Hepatitis B virus (HBV) infection is associated with liver diseases, including chronic hepatitis, which notably increases the risk of cirrhosis and hepatocellular carcinoma (HCC) development. Although ...